Our objective is to characterize the long-term course of Glut1 deficiency syndrome. Longitudinal outcome measures, including Columbia Neurological Scores, neuropsychological tests, and adaptive behavior reports, were collected for 13 participants with Glut1 deficiency syndrome who had been followed for an average of 14.2 (range = 8.9-23.6) years. A parent questionnaire assessed manifestations throughout development. The 6-Minute Walk Test captured gait disturbances and triggered paroxysmal exertional dyskinesia. All longitudinal outcomes remained stable over time. Epilepsy dominated infancy and improved during childhood. Dystonia emerged during childhood or adolescence. Earlier introduction of the ketogenic diet correlated with better long-term outcomes on some measures. Percent-predicted 6-Minute Walk Test distance correlated significantly with Columbia Neurological Scores. We conclude that Glut1 deficiency syndrome is a chronic condition, dominated by epilepsy in infancy and by movement disorders thereafter. Dietary treatment in the first postnatal months may effect improved outcomes, emphasizing the importance of early diagnosis and treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0883073814531822 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Human Genetic GLUT1 Deficiency Results in Impaired T Cellular IFN-γ Production.
Eur J Immunol
December 2024
Department of Pediatrics, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
GLUT1 deficiency prevents glucose uptake in T cells resulting in lower intracellular ATP generation and IFNy production.
View Article and Find Full Text PDFKetogenic diet therapy for the treatment of pediatric epilepsy.
Epileptic Disord
December 2024
Department of Neurology and Pediatrics, Johns Hopkins Hospital, Baltimore, Maryland, USA.
In 1921, the classic ketogenic diet was created at the Mayo Clinic in Rochester, Minnesota to treat epilepsy in children and adults. Over a century later, it is a widely used, standard-of-care therapy for typically treatment-resistant epilepsy worldwide. There are currently five versions of ketogenic diet therapy that can be started either in or out of the hospital setting.
View Article and Find Full Text PDFClinical, etiological, and therapeutic profile of early-onset absence seizures: A case series analysis.
Clin Neurol Neurosurg
December 2024
Pediatric Unit, Department of Medical and Surgical Sciences of Mothers, Children and Adults, University of Modena and Reggio Emilia, Modena 41121, Italy. Electronic address:
Typical absence seizures represent a distinctive form of epileptic activity typically observed in pediatric populations, predominantly manifesting between the ages of 4 and 10, constituting Childhood Absence Epilepsy (CAE). However, a subset of patients presents with Early-onset Absence Epilepsy (EOAE), characterized by seizure onset before the fourth year of life, often displaying favorable outcomes with antiseizure medication. Conversely, atypical absence seizures exhibit prolonged duration and frequently entail tonic, atonic, or myoclonic motor elements, suggesting a more severe clinical course, commonly associated with epileptic encephalopathies of childhood onset.
View Article and Find Full Text PDFA novel frameshift variant in the gene causing a mild phenotype of GLUT1 deficiency syndrome: case report.
Mol Genet Metab Rep
December 2024
Postgraduate Program in Genetics and Molecular Biology, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
Article Synopsis
- - GLUT1 deficiency syndrome is a genetic disorder that leads to low glucose levels in the brain, causing symptoms like seizures, developmental delays, and movement disorders, which can vary in severity.
- - Treatment typically involves a ketogenic diet that provides an alternative energy source for the brain.
- - The study identifies a new genetic mutation in a preschool child with atypical symptoms and highlights the need for genetic testing in patients with developmental delays.
Epileptiform activity in brain organoids derived from patient with Glucose Transporter 1 Deficiency Syndrome.
Front Neurosci
November 2024
GliaPharm SA, Geneva, Switzerland.
Introduction: Glucose Transporter 1-Deficiency Syndrome (GLUT1-DS) is a rare genetic disorder caused by mutations in the gene encoding for GLUT1 and characterized by impaired glucose uptake in the brain. This leads to brain hypometabolism and the development of symptoms that include epilepsy, motor dysfunctions and cognitive impairment. The development of patient-specific models is a valuable tool for understanding the pathophysiology of rare genetic disorders and testing new therapeutic interventions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!